Related Experiment Video
Updated: Jan 24, 2026
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Immune reaction by cytoreductive prostatectomy
Geun Taek Lee1, Arnav Srivastava1, Young Suk Kwon1
1Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey New Brunswick, NJ, USA.
Abstract:
Prostate cancer (PCa) is the most common non-cutaneous cancer among men and the second leading cause of male cancer deaths in the United States. With no effective cure for advanced disease, the survival rates of castration-resistant disease and metastatic disease remains poor. Treatment via hormonal manipulation, immunotherapy, and chemotherapy remain marginally effective, indicating the need for novel treatment strategies. Cytoreductive prostatectomy (CRP) has grown as a treatment modality for metastatic castration resistant prostate cancer (mCRPC) and an emerging body of literature has demonstrated its survival benefits. In this review, we hope to further explore immunologic changes after CRP and the resultant effects on oncologic outcomes. Conclusively, the data and technical considerations of CRS evolve, CRS may continue to expand treat various type of metastatic cancer. Still, there are little reports about immunological changed after CRP. However, based on technical improvement, CRP and combinational immunotherapy are developing treatments of metastatic disease.
Insights
Cytoreductive prostatectomy (CRP) shows survival benefits for advanced prostate cancer. Further research is needed on its immunologic effects and combination with immunotherapy for better metastatic disease treatment.
Area of Science:
- Oncology
- Immunology
Background:
- Prostate cancer (PCa) is a leading cause of cancer death in men, with poor survival rates for advanced and metastatic castration-resistant prostate cancer (mCRPC).
- Current treatments like hormonal manipulation, immunotherapy, and chemotherapy offer limited efficacy, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review the immunologic changes following cytoreductive prostatectomy (CRP) in patients with metastatic castration-resistant prostate cancer.
- To explore the impact of these immunologic changes on oncologic outcomes.
Main Methods:
- Literature review focusing on studies investigating immunologic responses post-CRP.
- Analysis of existing data on the efficacy and safety of CRP for mCRPC.
Main Results:
- Cytoreductive prostatectomy (CRP) is an emerging treatment modality for mCRPC with demonstrated survival benefits.
- There is limited published data specifically detailing the immunological alterations induced by CRP.
Conclusions:
- CRP is a promising treatment for various metastatic cancers, with ongoing technical advancements.
- CRP combined with immunotherapy represents a developing treatment approach for metastatic disease, warranting further investigation into its immunological effects.
More Related Videos
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
Related Concept Videos
02:06Allergic Reactions
01:38What is the Immune System?
01:36Humoral Immune Responses
03:06Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
02:53Determining Order of Reaction
02:22Reaction Yield